Arcellx anito-cel Phase 1 shows 100% ORR, 76% CR; median PFS 28 months at 26.5 mo follow-up

Arcellx, Inc.

100% ORR (38/38) with 76% achieving CR/sCR; median PFS estimated at 28 months with 26.5 mo median follow-up.
Safety: no grade ≥3 CRS, one grade 3 ICANS; no delayed neurotoxicity or parkinsonian symptoms reported.
All 38 patients were triple-refractory; 68% penta-refractory; 63% had ≥1 high-risk clinical feature.
Upcoming oral presentation at ASH on Dec 11; company webcast with expert panel same day.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.